BCR and mantle cell lymphoma: Moreover, we observed a synergistic effect when ironomycin is combined with ibrutinib, leading to increased MCL cell death, suggesting that there is a therapeutic benefit in the combined approach of BCR inhibition and iron homeostasis targeting for the treatment of MCL patients.